Document Detail


Early development of acute myeloid leukemia following treatment of osteosarcoma: a case report and review of the literature.
MedLine Citation:
PMID:  19856869     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We report a case of treatment-related acute myeloid leukemia (t-AML) in a 16-year-old male following treatment for osteosarcoma (OS). He had been treated with a protocol comprising neoadjuvant chemotherapy, definitive surgery with wide excision and adjuvant chemotherapy for OS. Four months after completion of the treatment, a routine hemogram showed hyperleukocytosis with 90% blasts. Bone marrow aspirate and a chromosomal analysis disclosed acute myeloid leukemia (AML), M5b with 46, XY, t(11;19)(q23;p13.3). The t-AML was characterized by early development (just 4 months after completion of chemotherapy for OS) and generalized leukemia cutis. The patient received an alkylating agent (ifosfamide) and DNA topoisomerase II-targeted drugs (etoposide and doxorubicin). In terms of latency, cytogenetics, and presentation, DNA topoisomerase II-targeted drug-related leukemia seemed likely for this patient. Clinically, his leukemia cutis had developed during a nadir in white blood cell count after the first induction of chemotherapy for AML. The rapid progression and its refractoriness to chemotherapy were poor prognostic signs.
Authors:
Yu-Mei Shen; Giun-Yi Hung; Hsiu-Ju Yen; Ming-Yun Hsieh; Te-Kuei Hsieh
Related Documents :
16690529 - Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine ...
2754449 - Association of granulocytosis with poor prognosis in patients with acute myelogenous le...
2185339 - Report of the national cancer institute-sponsored workshop on definitions of diagnosis ...
10784399 - Acute myeloblastic leukemia secondary to myelodysplasia (mds-aml): a comparison of remi...
16105759 - Aclarubicin and low-dose cytosine arabinoside in combination with granulocyte colony-st...
19717379 - Cladribine in the treatment of acute myeloid leukemia: a single-institution experience.
24730769 - Evaluation of the clinical characteristics and prognostic factors of gastrointestinal m...
8471559 - A phase ii study of weekly edatrexate (10-edam) in metastatic melanoma. a national canc...
11408499 - Clinicopathologic features of long-term survivors and disease-free survivors after rese...
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  Pediatrics and neonatology     Volume:  50     ISSN:  1875-9572     ISO Abbreviation:  -     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-10-27     Completed Date:  2009-11-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101484755     Medline TA:  Pediatr Neonatol     Country:  Singapore    
Other Details:
Languages:  eng     Pagination:  239-44     Citation Subset:  IM    
Affiliation:
Department of Pediatrics, Hsin Chu General Hospital, Hsinchu, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Antineoplastic Agents, Alkylating / adverse effects
Bone Neoplasms / drug therapy*
DNA Topoisomerases, Type II / antagonists & inhibitors
Humans
Leukemia, Myeloid, Acute / etiology*
Male
Neoplasms, Second Primary / etiology*
Osteosarcoma / drug therapy*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Alkylating; EC 5.99.1.3/DNA Topoisomerases, Type II

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pfeiffer-like syndrome with holoprosencephaly: a newborn with maternal smoking and alcohol exposure.
Next Document:  Thromboelastometry--a new method supporting the therapeutical decisions in the coagulopathy based on...